International Course on Antibiotics and Resistance ICARe, 11-19 Nov 2017

Dear All:

FYI, see below an announcement of an 8-day intensive course in Paris in November 2017: “ICARe is designed for early career scientists – assistant professors, new industry scientists, MDs, and postdoctoral research associates – as well as members from developing areas contending with the practical challenge of managing the antibiotic resistance problem with limited resources. Attendance will be limited to 40 students and will reflect the global nature of the problem.”

Also keep in mind the 6-8 Sep ASM-ESCMID conference in Boston on antibacterial drug development along with its preceding co-sponsored (CARB-X + ASM-ESCMID) workshop. 

–jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust
Follow me on Twitter: @JohnRex_NewAbx


Dear Colleague,

We are organizing the second edition of the International Course on Antibiotics and Resistance (ICARe) which will be held at the Fondation Mérieux, Annecy, France, November 11-19, 2017 (download flyer and course outline here).

The specific goal of ICARe is to bring leaders in academics and industry together with trained scientists at the dawn of their careers. Cutting-edge approaches for understanding and detection of resistance, antibiotic discovery, chemical optimization, and use of strategies that minimize the development of resistance will be examined.

Our course aims at providing future leaders in the field of antibiotics and resistance with the information they do not usually get in graduate or medical school, but that they need to make a serious contribution to solving the problem. In the past, they would receive some of that training once they joined a well-established antibiotic discovery program in pharma.  But more of the needed discoveries now rely on academic researchers with little or no experience, and many are spinning out biotech ideas without really understanding the challenges.

You can use the flyer to advertise for the course and the outline is to incite you to send your most promising collaborators.

Thank you in advance for your help,

P. Courvalin, M. Gilmore, G. Wright

Share

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1 Dear All (and with thanks to Kevin Outterson for being lead author on this newsletter), (wonkish alert on this one … refresh your coffee and dig in!) The Center for Global Development have released a blog post and a paper estimating the potential impact of the PASTEUR Act.

Five FDA RFPs! Antifungal animal models, MIC breakpoints, and more!

Dear All, I just today learned that FDA have posted their FY 2023 funding opportunities. All the details are on this webpage and I’m just going to reproduce the text below my signature for your reference. I’ll also add a few details in italics. Lots of good opportunities here! –jr John H. Rex, MD |

WAAW! Must-Read Article, A Quiz, A Video, A Call to Action

Notes: Newsflash … BARDA have opened their long-running BAA-18-100-SOL-00003 to include support for antifungal agents. Search for “antifungal” in the posted .pdf to find the text. The first deadline for proposals is 15 Dec 2022 and further deadlines will doubtless follow: as shown on page 9, this BAA has offered 4 deadlines/year since 2018!  Dear All, In

Fireside Chat with AMR Action Fund CIO Martin Heidecker

Dear All, Ahead of World Antimicrobial Awareness Week, I sat down with AMR Action Fund Chief Investment Officer Martin Heidecker for a Fireside Chat. It was a fabulous conversation that covered everything from how the Fund’s investment process works to what it’s looking for in portfolio companies to broader investment trends in the AMR space.  As

Scroll to Top